Takeda’s 2,025% Return in Novartis Deal Shows Pharma’s Upside

(Bloomberg) -- For a masterclass in the upside potential of pharma M&A, look no further than Takeda Pharmaceutical Co.’s sale of an eye drug to Novartis AG this week.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.